Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial-Reference-Cited by-同舟云学术

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

Published:2015-12 Issue:16 Volume:16 Page:1677-1690
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Place Andrew E,Stevenson Kristen E,Vrooman Lynda M,Harris Marian H,Hunt Sarah K,O'Brien Jane E,Supko Jeffrey G,Asselin Barbara L,Athale Uma H,Clavell Luis A,Cole Peter D,Kelly Kara M,Laverdiere Caroline,Leclerc Jean-Marie,Michon Bruno,Schorin Marshall A,Welch Jennifer J G,Lipshultz Steven E,Kutok Jeffery L,Blonquist Traci M,Neuberg Donna S,Sallan Stephen E,Silverman Lewis B

Funder

Enzon Pharmaceuticals

Dana-Farber Cancer Institute

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01;Silverman;Blood,2001

2. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis;Kearney;Pediatr Blood Cancer,2009

3. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols;Grace;Br J Haematol,2011